Nose drops with friendly bacteria could pave way for meningitis vaccine

NCT ID NCT03549325

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study gave healthy adults nose drops containing a harmless bacteria (N. lactamica) to see how the body's immune system responds. The goal is to learn if the immune response is the same whether the bacteria is cleared after 4 days or 14 days. This information will help design a future vaccine to prevent meningitis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

21 people

The number who actually took part.

Started

Mar 2017

Finished

Dec 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy adults aged 18 to 45 years inclusive on the day of enrolment * Fully conversant in the English language * Able and willing (in the investigator's opinion) to comply with all study requirements * Written informed consent to participate in the trial * Willingness to take an antibiotic regimen after inoculation according to the study protocol * For females only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and inoculation Exclusion Criteria: * Current active smokers * N. lactamica or N. meningitidis detected on throat swab or nasal wash taken before the challenge * Individuals who have a current infection at the time of inoculation * Individuals who have been involved in other clinical trials involving receipt of an investigational product over the last 12 weeks or if there is planned use of an investigational product during the study period * Individuals who have previously been involved in clinical trials investigating meningococcal vaccines or experimental challenge with N. lactamica * Use of systemic antibiotics within the period 30 days prior to the challenge * Any confirmed or suspected immunosuppressive or immune-deficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (topical steroids are allowed) * Use of immunoglobulins or blood products within 3 months prior to enrolment. * History of allergic disease or reactions likely to be exacerbated by any component of the inoculum * Contraindications to the use of ciprofloxacin, specifically a history of epilepsy, prolonged QT interval, hypersensitivity to quinolones or a history of tendon disorders related to quinolone use * Any clinically significant abnormal finding on clinical examination * Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data, for example recent surgery to the nasopharynx * Occupational, household or intimate contact with immunosuppressed persons * Pregnancy or lactation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Meningitis, meningococcal are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Southampton NIHR Clinical Research Facility

    Southampton, Hampshire, SO166YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.